公开(公告)号：WO2012067822A1

公开(公告)日：2012-05-24

申请号：PCT/US2011/058939

申请日：2011-11-02

Applicant: ABBOTT LABORATORIES ,  XU, Xiandong ,  VAN CAMP, Jennifer ,  SCANIO, Marc J. ,  BUNNELLE, William H. ,  SHI, Lei ,  OSUMA, Augustine T. ,  DEGOEY, David ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar ,  PATEL, Jyoti R.

Inventor： XU, Xiandong ,  VAN CAMP, Jennifer ,  SCANIO, Marc J. ,  BUNNELLE, William H. ,  SHI, Lei ,  OSUMA, Augustine T. ,  DEGOEY, David ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar ,  PATEL, Jyoti R.

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00

CPC classification number: C07D487/04

Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Abstract translation: 本文公开了式（I）的KCNQ钾通道调节剂，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。 包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：EP1751108A1

公开(公告)日：2007-02-14

申请号：EP05742013.5

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES

Inventor： LINK, James T. ,  PLIUSHCHEV, Marina A. ,  ROHDE, Jeffrey J. ,  WODKA, Dariusz ,  PATEL, Jyoti R. ,  SHUAI, Qi

IPC: C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D207/02 ,  A61K31/44 ,  A61K31/445

CPC classification number: C07D213/06 ,  C07C237/04 ,  C07C237/24 ,  C07C2601/02 ,  C07C2603/74 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。